Connect with us

Health

Cannabis and Cocaine Top Drug Use in the EU, but Other Substances Pose Rising Risks

Published

on

Cannabis and cocaine remain the most commonly used drugs across the European Union, but other substances are emerging as significant public health threats, according to a joint report by the European Commission and the Organisation for Economic Co-operation and Development (OECD).

Nearly one in three Europeans have tried illegal drugs at some point in their lives. Regular drug use is linked to heightened risks of cardiovascular disease, mental health problems, accidents, and infectious diseases like HIV, particularly with injectable substances.

Cannabis and Cocaine Usage

Cannabis use is especially prevalent among young adults, with 15% reporting consumption in the past year. Among all age groups, the highest rates of cannabis use were found in the Czech Republic, Italy, France, and Spain. In contrast, Malta, Turkey, and Hungary reported the lowest rates.

Cocaine use is less common but remains significant, with 2.5% of young adults reporting use in the past year. The Netherlands, Spain, and Ireland report the highest rates of cocaine use, while Turkey, Portugal, Poland, and Hungary show the lowest prevalence.

Law Enforcement Impact

Strict drug penalties appear to have limited influence on drug availability for younger populations. “The major penalties impact only the people who use the substance once or fewer times in a year, so not the real [heavy] users,” explained Sabrina Molinaro, an epidemiologist and research director at Italy’s National Research Council.

Drug habits among youth often predict adult trends, Molinaro noted. Historically, boys were more likely than girls to use cannabis, but that gap has narrowed in recent years, with girls surpassing boys in some countries.

Growing Risks from Other Drugs

While cannabis and cocaine dominate drug use in the EU, substances like MDMA (ecstasy), heroin, opioids, psychedelics, and synthetic drugs are emerging as critical threats. Synthetic drugs, including lab-made cannabinoids and stimulants, pose unique challenges because they are difficult to identify and regulate quickly.

“They are so dangerous [because] you don’t know what you are taking,” said Molinaro, emphasizing the risks posed by low-quality manufacturing and potential contamination.

The EU dismantled hundreds of synthetic drug labs in 2022, and its early warning system identified seven new synthetic opioid substances in 2023, noted for their potency and health risks.

Public Health Concerns

Synthetic drugs, in particular, are a growing issue among adult populations, according to Molinaro. With the rise in new substances and increasing drug availability, experts are calling for more robust measures to address these evolving challenges.

The report underscores the need for comprehensive approaches to tackle drug use and its health implications across the EU, including better monitoring, education, and targeted interventions.

Health

Papua New Guinea Launches Emergency Polio Response After New Cases Detected

Published

on

Health authorities in Papua New Guinea have launched an urgent national vaccination campaign following the detection of two polio cases in children, marking the country’s first confirmed outbreak of the virus since 2018.

The Ministry of Health confirmed this week that poliovirus was found in two otherwise healthy children during routine screenings. Subsequent testing of sewage samples in Lae, the country’s second-largest city, verified that the virus is circulating in the community.

Health Minister Elias Kapavore described the situation as “serious but manageable” and urged swift action. “We’ve dealt with this before and know what works,” he said in a public statement, referring to a previous outbreak in 2018 that resulted in 26 cases of paralysis.

Although Papua New Guinea was declared polio-free in 2000, the recent cases underscore the country’s vulnerability due to persistently low vaccination rates among children. Polio, a highly contagious viral disease, primarily affects children under five and can lead to irreversible paralysis or death in severe cases. The disease has been largely eradicated globally, with only a few endemic regions remaining, such as Afghanistan and Pakistan.

The United Nations Children’s Fund (UNICEF) is working closely with the government to support the emergency vaccination drive. “While the focus right now is on stopping this outbreak, we must take this opportunity to boost routine immunisation to 90 per cent and protect children long-term,” said Dr Veera Mendonca, UNICEF’s representative in Papua New Guinea.

Mendonca emphasised that a long-term strategy to raise routine immunisation coverage is essential to prevent future outbreaks. UNICEF is also assisting in disease surveillance and public education efforts to raise awareness of the risks posed by polio and the importance of vaccination.

The outbreak response will target communities across the country, with particular focus on areas with the lowest immunisation coverage. Health officials are urging parents to ensure their children receive the polio vaccine, which remains the only effective way to prevent infection.

With a population of nearly 12 million and significant logistical challenges in remote areas, ensuring high vaccination coverage will be a complex task. However, authorities remain confident in their ability to contain the outbreak with coordinated action and international support.

Continue Reading

Health

Healthy Diet May Delay Onset of Menstruation, Study Finds

Published

on

A healthy diet may help delay the onset of menstruation in young girls, potentially reducing their risk of several health issues later in life, according to new research published in the journal Human Reproduction.

The study, conducted by researchers at the Fred Hutchinson Cancer Center in the U.S., followed over 7,500 girls between the ages of 9 and 14 to explore the link between dietary habits and the timing of their first menstrual periods. Girls who adhered to the healthiest diets were found to be 16% less likely to experience early menstruation compared to those with the poorest dietary habits.

In contrast, girls who consumed the most inflammatory foods — such as processed meats, sugary drinks, and refined carbohydrates — were 15% more likely to begin menstruating at an earlier age. These results were independent of body size, reinforcing the impact of diet quality regardless of a child’s weight or height.

These findings demonstrate the importance of a healthy diet regardless of body size,” said Dr. Holly Harris, lead author of the study and associate professor at Fred Hutchinson Cancer Center. “This is particularly relevant as early menstruation has been associated with long-term health risks including obesity, type 2 diabetes, cardiovascular disease, and breast cancer.”

Typically, girls begin puberty between the ages of 8 and 13, with menstruation occurring roughly two years after breast development. However, a trend toward earlier onset of puberty has raised concerns among health professionals, especially given its links to chronic illnesses in adulthood.

While the study highlights a possible role for diet in influencing menstrual timing, some experts have cautioned against drawing firm conclusions. Dr. Imogen Roger, a research fellow at Brighton and Sussex Medical School, noted that the data may reflect “reverse causation” — suggesting that the timing of puberty itself might influence dietary choices, rather than the reverse.

Diet was assessed close to the time of menarche for many of the girls,” Roger told Euronews Health. “We know that diet quality can decline during adolescence, so the association may not be entirely one-way.”

Nonetheless, researchers agree that ensuring children have access to nutritious foods — particularly during the crucial developmental window around puberty — is vital. Harris emphasized the importance of school meal programmes grounded in evidence-based nutrition.

This research reinforces the need for equitable access to healthy meals for all children and adolescents, especially through school-based initiatives,” she said.

Continue Reading

Health

Europe Pays Less for Medicines Than the U.S., but Prices Still Vary Widely by Country

Published

on

As former U.S. President Donald Trump reignites debate over America’s high drug prices, attention is once again turning to how Europe manages to pay far less for the same medicines—even if pricing remains inconsistent across the continent.

Trump, speaking to journalists on Monday, criticized the European Union for what he called “brutal” and “nasty” tactics in negotiating with pharmaceutical companies. He announced a proposal to link U.S. drug prices to the lowest rates paid by other wealthy nations, declaring: “We’re going to pay what Europe pays.”

According to a RAND Corporation analysis, the U.S. spent $617.2 billion (€542.7 billion) on pharmaceuticals in 2022—nearly three times the €205.3 billion spent by 24 European countries combined.

While it’s true that Europeans generally pay less, the picture within the region is far from uniform. A report by the World Health Organization (WHO) found that drug prices vary widely across Europe, largely due to confidential negotiations with drugmakers, national budget constraints, and differing approaches to price regulation.

In Switzerland, per capita spending on medicines reached €525, whereas Croatia spent just €262. These discrepancies reflect not only national income levels but also the complex and opaque nature of price-setting in the region. “There’s essentially no transparency,” said Huseyin Naci, an associate professor of health policy at the London School of Economics.

Many European countries base their pricing on what other nations pay and use cost-effectiveness assessments to determine value. England and Sweden emphasize whether a drug justifies its cost, while Germany looks at how much additional benefit it offers over existing treatments.

Still, costs have risen across the continent. In Germany, for instance, hospital drug prices increased 11.5% from 2012 to 2022, while retail pharmacy prices rose 2.6% in the same period. Health insurers have warned that rising prices are putting pressure on public health budgets.

If U.S. policy changes or drug companies push European nations to raise their prices, it would be highly disruptive,” Naci said.

European nations also differ in how drug costs are shared between public systems and individuals. In Cyprus, 90% of medicine expenses were covered by government or mandatory schemes in 2022. In Bulgaria, that figure was only 23%. Meanwhile, patients in some countries still pay out-of-pocket or through co-payments, depending on the condition being treated.

Despite lower overall spending, experts caution that European healthcare systems are already stretched thin. “There’s not much room left to absorb higher pharmaceutical costs,” Naci said.

Continue Reading

Trending